Short Interest in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Drops By 6.1%

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,130,000 shares, a decrease of 6.1% from the January 15th total of 7,590,000 shares. Based on an average daily trading volume, of 368,500 shares, the days-to-cover ratio is presently 19.3 days.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 5,104 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $50,121.28. Following the transaction, the chief executive officer now owns 278,855 shares of the company's stock, valued at $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Paul K. Audhya sold 3,125 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the transaction, the insider now directly owns 100,334 shares in the company, valued at $985,279.88. The trade was a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 236,055 shares of company stock valued at $2,162,146 and have sold 18,043 shares valued at $176,758. 10.50% of the stock is currently owned by corporate insiders.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its stake in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock valued at $123,000 after acquiring an additional 1,319 shares during the period. HighVista Strategies LLC boosted its position in shares of KalVista Pharmaceuticals by 4.5% in the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company's stock worth $386,000 after buying an additional 1,432 shares during the period. Legal & General Group Plc grew its stake in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 1,494 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of KalVista Pharmaceuticals by 8.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock valued at $262,000 after buying an additional 1,670 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after buying an additional 2,043 shares during the period.

KalVista Pharmaceuticals Stock Down 5.7 %

KalVista Pharmaceuticals stock traded down $0.61 during mid-day trading on Friday, hitting $10.03. The company had a trading volume of 447,802 shares, compared to its average volume of 309,626. The stock has a market cap of $495.68 million, a price-to-earnings ratio of -2.76 and a beta of 0.85. The business has a fifty day moving average of $8.84 and a 200 day moving average of $10.43. KalVista Pharmaceuticals has a 1 year low of $7.30 and a 1 year high of $15.50.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.01. Equities analysts anticipate that KalVista Pharmaceuticals will post -3.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a "buy" rating and a $22.00 price target on the stock. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an "outperform" rating and a $19.00 price target on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).